Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
When Context Changes a Yield Result
2026-11-20
A reported 15–20 g/L milk concentration in a targeted rabbit line is meaningful only within its genetic, biological and measurement context. The result supports a proof of concept for expression from the endogenous CSN2 locus, but it does not establish equivalent performance for therapeutic proteins, long-term production consistency or any role for HEPES.
PLGA–Alarelin and Pikeperch Sperm Quality
2026-11-20
A preliminary study in 32 mature male pikeperch found that PLGA-mediated alarelin treatment was associated mainly with later sperm-motility differences rather than increased sperm quantity. The findings support biological activity in a specific formulation and reproductive context, but do not establish fertilization benefit or standalone product efficacy.
mRNA-LNP Translation: Why CMC Matters
2026-11-19
A literature-focused analysis of how lipid chemistry, manufacturing control, analytical characterization, and comparability shape the translation of mRNA lipid nanoparticles from promising formulations to clinically credible products.
How mRNA-LNP Chemistry Shapes Translation
2026-11-19
The translation of mRNA therapeutics depends on more than RNA sequence or particle formation. Lipid ionization, intracellular trafficking, manufacturing history, and orthogonal quality measurements jointly determine whether a formulation can connect molecular design with reproducible biological performance.
mRNA-LNP Translation: What CMC Evidence Shows
2026-11-18
A review-based synthesis of how lipid chemistry, critical quality attributes, manufacturing comparability, and analytical controls shape the translation of mRNA lipid nanoparticles. The evidence concerns mRNA-LNP systems and does not establish performance for cell-freezing media.
What CMC Evidence Really Shows for mRNA-LNPs
2026-11-18
A source-grounded editorial explains how lipid chemistry, manufacturing control, analytical characterization, and physiological stability jointly shape the translation of mRNA lipid nanoparticles—and where current evidence remains qualitative.
How mRNA-LNP Translation Depends on CMC
2026-11-17
A literature-focused analysis of how lipid chemistry, particle attributes, manufacturing comparability, and analytical controls shape the translation of mRNA lipid nanoparticles from research concepts toward clinically credible products.
When Context Changes What an mRNA Result Means
2026-11-17
A result in mRNA delivery is meaningful only when its model, readout, manufacturing context, and intended use are considered together. The evidence distinguishes formulation performance from physiological stability, reproducibility, tolerability, and clinical translation.
What Makes mRNA–LNP Translation Credible?
2026-11-16
A 2026 review frames mRNA–lipid nanoparticle translation as a chain linking lipid chemistry, manufacturing attributes, analytical controls, and clinical performance. Its strongest contribution is a CMC-oriented interpretation of how these factors interact; it does not provide a quantitative head-to-head efficacy analysis for any particular formulation.
What mRNA-LNP Comparisons Really Establish
2026-11-16
Published comparisons support lipid nanoparticles as the most clinically established nonviral delivery platform for mRNA, but they do not resolve how lipid chemistry, manufacturing route, quality attributes, and physiological stability jointly determine clinical performance.
What mRNA-LNP Comparisons Really Establish
2026-11-15
Published comparisons support a trade-off-based view of mRNA delivery: ionizable lipids offer a different balance of delivery, tolerability and clearance than permanently cationic lipids, while lipid nanoparticles retain stronger clinical and regulatory precedent than polymeric or hybrid alternatives. The central uncertainty is not whether one platform is universally best, but how chemistry, critical quality attributes, manufacturing changes and biological context jointly determine performance.
What Controls mRNA–LNP Translation?
2026-11-14
A claim-oriented synthesis of how lipid chemistry, critical quality attributes, manufacturing comparability, and physiological stability shape the translation of mRNA lipid nanoparticles—and where the current evidence remains indirect.
What Controls mRNA–LNP Translation?
2026-11-13
A literature-focused analysis of how lipid chemistry, manufacturing control, analytical characterization, and comparability planning shape the translation of mRNA lipid nanoparticles from delivery concepts into clinically credible products.
Why Context Changes a Scientific Result
2026-11-13
A measurement in RNA delivery acquires meaning from its model, comparator, assay endpoint, manufacturing history, and physiological setting. This editorial examines how those contexts alter interpretation, using a review of mRNA lipid nanoparticle translation as the evidentiary frame.
Multiplex CRISPR: What Comparisons Establish
2026-11-12
Published comparisons support multiplex CRISPR as a flexible platform for coordinated gene disruption, structural-variant modeling and regulatory perturbation. They do not yet establish a universal advantage across cell types, targets or delivery systems. The central unresolved issues are how editing breadth changes specificity and cellular stress, whether reported efficiencies generalize, and how engineering trade-offs affect clinical applicability.